anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The therapeutic scheme was modified FOLFOX6 regimens including oxaliplatin (130 mg/m2 infusion for 3 hours on day 1), leucovorin (200 mg/m2 from hour 3 to 5 on day 1) and Fluorouracil (400 mg/m2 in bolus, and then 2,400 mg/m2 continuous infusion 46 hours). All chemo-drugs were given by HAI.Patients received anti-PD-L1 agents will begin no earlier than 7 days following the first HAIC procedure. Anti-PD-L1 agents were used intravenously at the standard dose: Durvalumab was given every 3 weeks during HAIC treatment (Q3W) and every 4 weeks after HAIC treatment (Q4W).
Chaihu-jia-Longgu-Muli decoction (CLMD) has been proven clinically effective in treating vertigo with anxiety disorder. However, the mechanism is not clear. This study aimed to explore the mechanism of CLMD in treating vertigo with anxiety disorder based on ultra-performance liquid chromatography-quadrupole time-of-flight/mass spectrometry (UPLC-Q-TOF/MS) and network pharmacology. UPLC-Q-TOF/MS was performed to identify the compounds in blood and the targets of compounds of CLMD in vertigo and anxiety were searched using databases. A protein-protein interaction network was built to screen the core targets. The core targets were analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. In addition, the vertigo with anxiety rat model was used to verify the results. A total of 22 compounds were absorbed into the blood. Eighty-one potential targets associated with CLMD for vertigo with anxiety disorder were identified through network pharmacological analysis. Subsequently, GO and KEGG analysis showed that CLMD treatment for vertigo with anxiety disorder is associated with neurotransmitter levels and other pertinent physiological processes. The results of the animal experiments showed that CLMD decreased the levels of serotonin, norepinephrine and dopamine, alleviating the symptoms of vertigo and anxiety disorder in model rats. The study revealed CLMD could alleviate vertigo and anxiety symptoms through reducing the levels of neurotransmitters.
Chimeric antigen receptor (CAR) T-cell therapy is an innovative treatment approach that has shown remarkable efficacy against several hematologic malignancies. However, its use can be associated with unique and sometimes severe toxicities that require admission to intensive care unit in 30% of patients, and intensivists should be aware of immune-mediated toxicities of CAR T-cell therapy and management of adverse events. We will review available literature on current diagnostic criteria and therapeutic strategies for mitigating these most common toxicities associated with CAR T-cell therapy including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in the post-infusion period. The authors will also review other toxicities associated with CAR T-cell therapy including cytopenias, acquired immunocompromised states, and infections, and discuss the available literature on best supportive care and prophylaxis recommendations. Critical care medicine specialists play a crucial role in the management of patients undergoing CAR T-cell therapies. With the expanding use of these products in increasing numbers of treating centers, intensivists' roles as part of the multidisciplinary team caring for these patients will have an outsized impact on the continued success of these promising therapies.
Topoisomerases alter DNA topology by making transient DNA strand breaks (DSBs) in DNA. The DNA cleavage reaction mechanism includes the formation of a reversible protein/DNA complex that allows rapid resealing of the transient break. This mechanism allows changes in DNA topology with minimal risks of persistent DNA damage. Nonetheless, small molecules, alternate DNA structures, or mutations in topoisomerase proteins can impede the resealing of the transient breaks, leading to genome instability and potentially cell death. The consequences of high levels of enzyme/DNA adducts differ for type I and type II topoisomerases. Top1 action on DNA containing ribonucleotides leads to 2-5 nucleotide deletions in repeated sequences, while mutant Top1 enzymes can generate large deletions. By contrast, small molecules that target Top2, or mutant Top2 enzymes with elevated levels of cleavage lead to small de novo duplications. Both Top1 and Top2 have the potential to generate large rearrangements and translocations. Thus, genome instability due to topoisomerase mis-function is a potential pathogenic mechanism especially leading to oncogenic progression. Recent studies support the potential roles of topoisomerases in genetic changes in cancer cells, highlighting the need to understand how cells limit genome instability induced by topoisomerases. This review highlights recent studies that bear on these questions.
1,247,614. Allergen extracts. MILES LABORATORIES Inc. 20 June, 1969, No. 31428/ 69. Heading A5B. Extracts of substances capable of producing an allergic response are produced by extracting the substance with a mixture of water and an organic solvent which contains basic nitrogen, e.g. a heterocylic tertiary amine such as pyridine, quinoline, lutidine, collidine or picoline, separating the liquid from all solid material and volatilising it to produce a dry, stable, powder. The liquid extract may be sterilized, e.g. by filtration and may be used in curative and diagnostic preparations. The extract may be further treated by redissolving the powder in water and precipitating an active substance from the solution by addition of a precipitating agent such as potash alum.
PURPOSE:To provide the subject substance produced by a brain-derived astroglia, containing alpha2-macroglobulin as the main component, useful as a medicine for reproduction of denaturated nerve tissue, prevention of scnescence, etc., and capable of promotion of neurite growth. CONSTITUTION:The cerebral hemisphere of an SD rat is taken out and treated with trypsin and the resultant free cells are filtered and flask cultured. Cells except astroglia are removed by the shaking method and secondary culture is carried out. The obtained astroglia is washed and then further cultured and the culture solution is recovered, thus preparing an astroglia culture supernatant. To the resultant supernatant ammonium sulfate is added and the generated precipitate is collected. The collected precipitate is dialyzed using a phosphate buffered saline, washed and then eluted to pool an active fraction and concentration thereof is carried out.
In a surgical procedure electrodes are inserted into muscles of the lower extremities to correct hip, knee and ankle function. The electrode leads are connected to an implanted pulse generator located in the abdomen. After a typical post-operative period of two to five days, the recipient will be discharged home for two to six weeks of moderate activity. Following a 6 week period of laboratory exercise and training, functional use of the neuroprosthesis will begin at home and in the community with follow-up evaluations at 1, 3, 6 and 12 months. Laboratory assessments include walking speed and distance, physiologic cost, muscle strength, measure of spasticity, and gait analysis with and without stimulation. A number of self-reporting instruments are administered to capture individual's participation, quality of life and various aspects of perceived community ambulation.
Subjects received a single oral dose of 160 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step.
This study will recruit a total of 130 gastric cancer patients. It is expected to recruit about 250 gastric cancer patients per year. Since the incidence of each mutation is low, the different types of mutations are assumed to be mutually exclusive. So, about 30% of these patients are expected to have a mutation with a target drug. Overall response (OR) is the primary endpoint of this study. OR rate (ORR) will be compared between the group (called targeted group) of patients who have a mutation with a target drug and that (called untargeted group) of patients who have no mutation. The ORR is expected to be about 25% for the targeted group and about 5% for the untargeted group. With N=130 gastric cancer patients, about 39 patients will belong to the targeted group and about 91 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 89% of power. The study on gastric cancer will take 7 months for patient accrual.
A prospective, pilot, cohort study design will recruit participants to train intensively for a 3 month period. The training sessions will be documented in detail, including number of steps taken, speed of walking, distance of walking. Once walking speed has plateaued, we will evaluate the feasibility of using the device in a home-like environment and in the community.

At the end of this study, we will have a good idea of the capability of the ReWalk to assist walking in those with severe spinal cord injury. We will better understand which individuals are most likely to benefit from the ReWalk. We will know how training in the ReWalk changes the neural connections between the brain and the spinal cord so that we can better guide the training protocol. Finally, we will identify limitations of the ReWalk for home and community use, so that exoskeletons can be improved in the future to maximize their benefit to people with spinal cord injury.
The present invention relates to a composition for skin regeneration, anti-wrinkling, antioxidant, anti-inflammatory and skin whitening activities. According to the present invention, arenobufagin promotes collagen generation of fibroblasts in the skin and thus has effects of regenerating skin and reducing wrinkles. Arenobufagin inhibits generation of free radicals and thus has an anti-oxidant effect. Arenobufagin also inhibits generation of NO and thus has an anti-inflammatory effect. In addition, arenobufagin inhibits synthesis of melanin and thus has a skin whitening effect. Therefore, the composition can be used as a pharmaceutical composition, an external use skin formulation, a cosmetic composition, or health food. The composition includes a compound represented by chemical formula 1 as an active ingredient.
Lung inflammatory disorders are a major global health burden, impacting millions of people and raising rates of morbidity and death across many demographic groups. An industrial chemical and common environmental contaminant, formaldehyde (FA) presents serious health concerns to the respiratory system, including the onset and aggravation of lung inflammatory disorders. Epidemiological studies have shown significant associations between FA exposure levels and the incidence and severity of several respiratory diseases. FA causes inflammation in the respiratory tract via immunological activation, oxidative stress, and airway remodelling, aggravating pre-existing pulmonary inflammation and compromising lung function. Additionally, FA functions as a respiratory sensitizer, causing allergic responses and hypersensitivity pneumonitis in sensitive people. Understanding the complicated processes behind formaldehyde-induced lung inflammation is critical for directing targeted strategies aimed at minimizing environmental exposures and alleviating the burden of formaldehyde-related lung illnesses on global respiratory health. This abstract explores the intricate relationship between FA exposure and lung inflammatory diseases, including asthma, bronchitis, allergic inflammation, lung injury and pulmonary fibrosis.
While it has been over half a century since primary cross-facial nerve grafting was first described for facial reanimation, the outcome of this procedure, remains inconsistent and provide lesser smile excursion when compared to the likes of the masseteric nerve. However, the latter itself has limitations in terms of the lack of spontaneity and resting tone. While combinations have been attempted more proximally, we ask the question as to whether more distal nerve transfers with vascularized nerve grafts are a better option. In a retrospective review of clinical practice at our institute, 16 consecutive patients had single, double, and finally triple distal nerve transfers, close to the target facial muscle to reinnervate the motor endplates directly, over a 6-year period (2018-23). All patients had the onset of facial palsy within 18 months. Statistical analysis of the comparison between three sub-cohorts was performed using student's t-test and one-way ANOVA, respectively. Qualitatively, masseteric neurotization of a single facial nerve branch translated into smile improvement in 50% of cases, as opposed to all cases of double- and triple-neurotization of the smile muscles. In terms of upper lip elevation, single neurotization showed improvement in 25% of cases, double-neurotization in 40% of cases and triple-neurotization in 100% of cases. Upper lip elevation was also significantly better in those who had a vascularized cross-facial nerve graft (Student's t-test <0.05). In summary, increasing neural input to the motor endplates of smile muscles can significantly improve smile activation, in acute flaccid facial palsies.
The present invention discloses an oral vanadium supplementing agent using bimetallic oxide as a carrier and preparation and use methods thereof. The oral vanadium supplementing agent is bimetallic oxide containing active vanadium. The content of vanadium in the bimetallic oxide is from 0.01% to 0.5% measured by weight percentage. The preparation method comprises: the temperature of hydrotalcite is increased to 450 to 550 DEG C to obtain the bimetallic oxide, vanadium anions are planted in crystal lattices by the property of absorbing anions of the bimetallic oxide, and finally, the bimetallic oxide is made into solid powder by dry grinding or spray drying or is pressed into tablets. The oral vanadium supplementing agent prepared based on the preparation method can provide the necessary trace element of the vanadium for human beings or animals through a slow release function, and alleviate various side effects brought by the direct oral administration of inorganic vanadium salts. The absorption rate of the vanadium is increased, and supplemented vanadium elements have the functions for promoting the growth and the reproduction of the animals, preventing and treating the vanadium deficiency diseases of the animals, treating the diabetes, the hemorrhagic anemia and the septicemia of the human beings, etc.
Metal keratinates are prepared by treating alkali metal keratinates, which are obtained from the non-reduced hydrolysis products of keratin, in weakly alkaline or acidic solution with so much of a salt of gold, silver, mercury, zinc, bismuth, antimony or copper that the product, when precipitated by addition of acid or organic solvents, contains at least 20 per cent of metal in the case of gold and bismuth and at least 12 per cent in the case of the remaining metals. The products possess therapeutic properties.  According to the examples: (1) a gold compound is obtained by adding an auric chloride solution slowly to a weakly alkaline solution of a keratinate prepared according to Specification 247,944, [Class 2 (iii)], until the precipitate just goes into solution; the solution is made weakly alkaline by addition of caustic soda solution and auric chloride solution again added until the precipitate dissolves; this process is repeated until, after precipitation with ethyl alcohol, a product is obtained containing 30 per cent of gold; (2) a bismuth compound containing 30 per cent of the metal is prepared by adding bismuth ammonium citrate to a weakly alkaline keratinate solution prepared according to Specification 247,944 and completing the precipitation with glacial acetic acid; (3) sodium antimonyl tartrate is added to a weakly alkaline keratinate solution prepared according to Specification 370,295; on stirring into alcohol, solid antimony keratinate settles out.  The alternate addition of alkali and metal salt solution is advantageous not only in the preparation of the gold compounds but also when using silver, mercury, zinc and copper salts. In the preparation of the bismuth and antimony compounds, the use of the organic metal double salts is desirable.  Specifications 357,189, 412,366, and 437,769 also are referred to.  The Specification as open to inspection under Sect. 91 also includes examples of the preparation of silver, mercury and lead keratinates by adding silver nitrate, mercury acetate and lead acetate solution respectively, alternately with soda lye, to a weakly alkaline solution of sodium keratinate and precipitating the product with alcohol.  This subject-matter does not appear in the Specification as accepted.
Chlordiazepoxide hydrochloride may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a vehicle or operating machinery. Similarly, it may impair mental alertness in children. The concomitant use of alcohol or other central nervous system depressants may have an additive effect. PATIENTS SHOULD BE WARNED ACCORDINGLY.

Usage in Pregnancy: An increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam and meprobamate) during the first trimester of pregnancy has been suggested in several studies. Because use of these drugs is rarely a matter of urgency, their use during this period should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physicians about the desirability of discontinuing the drug.

Withdrawal symptoms of the barbiturate type have occurred after the discontinuation of benzodiazepines. (See DRUG ABUSE AND DEPENDENCE section.)
This invention relates to a novel method for the delivery of cytotoxic drugs to tumor cells by the administration of a tumor-specific antibody-enzyme conjugate that binds to the tumor cells, and the additional administration of a prodrug that is converted at the tumor site, in the presence of the antibody-bound enzyme, to an active cytotoxic drug. According to preferred embodiments of this invention, antibody-enzyme conjugates containing the enzyme, alkaline phosphatase ("AP"), have been used in conjunction with the novel prodrug, etoposide-4′-phosphate or 7-(2′-aminoethyl phosphate)mitomycin or a combination thereof, to effect killing of tumor cells. According to another embodiment of the invention, an antibody-enzyme conjugate containing the enzyme, penicillin V amidase ("PVA"), has been used. in conjunction with a novel prodrug, N-( p -hydroxyphenoxyacetyl)adriamycin to effect killing of tumor cells. Still another embodiment of the invention relates to the use of an antibody-enzyme conjugate containing the enzyme, cytosine deaminase ("CD"), in combination with the prodrug, 5-fluorocytosine, to effect killing of tumor cells. The methods, antibody-enzyme conjugates, prodrugs, pharmaceutical compositions and combinations of this invention provide for enhanced selective killing of tumor cells and are thus useful in the treatment of cancers and other tumors.
Hyperthyroidism is becoming increasingly important as an independent risk factor for cardiovascular disease, eventually resulting in cardiac hypertrophy and heart failure. The 14-3-3 protein family subtypes regulate many cellular processes in eukaryotes by interacting with a diverse array of client proteins. Considering that the 14-3-3η protein protects cardiomyocytes by affecting mitochondrial function, exploring the biological influence and molecular mechanisms by which 14-3-3η alleviates the cardiac hypertrophy of hyperthyroidism is imperative. In vivo and in vitro, RT-PCR, Western blot, and Mitochondrial tracking assay were performed to understand the molecular mechanism of thyroxine-induced cardiomyocyte hypertrophy. HE staining, transmission electron microscopy, and immunofluorescence were used to observe intuitively changes of hearts and cardiomyocytes. The in vivo and in vitro results indicated that overexpression of the 14-3-3η ameliorated thyroxine-induced cardiomyocyte hypertrophy, whereas knockdown of the 14-3-3η protein aggravated thyroxine-induced cardiomyocyte hypertrophy. Additionally, overexpression of the 14-3-3η protein reduces thyroxine-induced mitochondrial damage and mitophagy in cardiomyocytes. Overexpression of 14-3-3η protein improves excessive mitophagy in the myocardium caused by thyroxine and thus prevents cardiac hypertrophy.
663,426. Anti-perspirant preparations. COLGATE-PALMOLIVE-PEET CO. June 29, 1949 [Dec. 11, 1948], No. 17163/49. Class 81 (i) An anti-perspirant preparation comprises aluminium sulphamate, and a discoloration inhibitor which is soluble in an aqueous solution of aluminium sulphamate and which does not precipitate therefrom a compound containing aluminium, and /or a fatty phase emulsified with an aqueous phase. Specified discoloration inhibitors are neutral amides or thioamides such as urea, ethyl carbamate, thiourea, formamide and acetamide; amino-carboxylic acids such as glycine, a-alanine and #-alanine; salts of a non-hydroxy carboxylic acid with an ammonia base such as diammonium malonate, ammonium acetate, diammonium oxalate, monoethanolamine acetate and triethanolamine acetate; and mercapto compounds such as sodium mercaptopropane sulphonate (1, 2), sodium 2-mercaptoethane-1-sulphonate, ammonium 2-mercaptoethane- 1-sulphonate, ammonium thioglycollate, thioglycollic acid and ethylene thiourea. The preparations may be in the form of aqueous solutions, or creams containing as the oil phase spermaceti, palmityl palmitate, polymerised ethylene oxide; paraffin, sterols, mineral and vegetable oils. Emulsifying agents such as partial esters of fatty acids with glycerine, glycol, &c., preferably in combination with a stabilizer such as the sodium salts of sulphated monoglycerides of coconut oil fatty acids, diethyloleylamid phosphate, sodium lauryl sulphate or sodium alkyl aromatic sulphonates, emollients such as glycerine, propylene glycol and sorbitol, and other additions such as titanium dioxide, stearyl alcohol and sodium #-oleylethane-amidosulphonate may be present in the creams.